Cognitive Peptides: Semax, Selank & Brain Health Research
Neuropeptide Science
Research Overview
Last Updated: May 2026
Cognitive peptides represent a distinct class of short-chain amino acid sequences with documented activity on central nervous system function — operating through mechanisms that differ fundamentally from classical small-molecule CNS drugs like benzodiazepines, amphetamines, or cholinesterase inhibitors. The most extensively researched cognitive peptides in the current neuroscience literature are Semax and Selank — both synthetic heptapeptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, with complementary mechanisms covering neurotrophic factor modulation, melanocortin receptor signalling, GABA system modulation, and enkephalinase inhibition. This guide provides a research-focused overview of what cognitive peptides are, how the primary mechanisms operate, and what the published evidence base for Semax and Selank actually shows. The Cognitive Focus Research Stack combines both compounds for researchers working across complementary CNS research areas.
Key Takeaways
- Cognitive peptides act on CNS function through receptor-mediated and enzymatic mechanisms — including neurotrophic factor modulation (BDNF, NGF), melanocortin receptor agonism, GABA-A receptor modulation, and enkephalinase inhibition — rather than through the broad monoamine reuptake inhibition of classical CNS drugs.
- Semax (MEHFPGP) is the best-characterised cognitive neuropeptide in terms of mechanism: its MC4R agonism drives BDNF and NGF upregulation in hippocampal and cortical regions, with neuroprotective effects characterised in ischaemia models. CAS: 80714-61-0.
- Selank (TKPRPGP) is the best-characterised cognitive neuropeptide in terms of anxiolytic pharmacology: its GABA-A system modulation and enkephalinase inhibition produce anxiolytic effects without the sedation or dependence liability of benzodiazepines. CAS: 129954-34-3.
- The mechanisms are complementary: Semax addresses neurotrophic factor-driven plasticity and neuroprotection; Selank addresses anxiety-mediated cognitive disruption and GABA/opioid signalling. Studying both allows mechanistic dissection of distinct CNS neuropeptide pathways.
- Russian clinical approval: Both Semax (stroke recovery) and Selank (GAD) are approved pharmaceutical drugs in Russia — providing a clinical literature base unusual for synthetic peptide research compounds. Neither has marketing authorisation in the UK or EU.
Cognitive Peptide Research — UK Supply
Semax and Selank available individually or as the Cognitive Focus Research Stack. HPLC ≥99% purity. Batch COA. For research purposes only.
What Are Cognitive Peptides?
Cognitive peptides are short amino acid sequences — typically 4–15 residues — that have demonstrated effects on central nervous system function in published research. The term encompasses both naturally occurring neuropeptides (endogenous compounds such as ACTH fragments, tuftsin, enkephalins) and synthetic analogs engineered for metabolic stability, selectivity, or potency.
The distinction between cognitive peptides and classical CNS pharmacology is mechanistic. Small-molecule cognitive drugs typically act through broad-spectrum receptor blockade or reuptake inhibition: methylphenidate inhibits dopamine and norepinephrine reuptake; modafinil modulates dopamine, norepinephrine, serotonin, and orexin; acetylcholinesterase inhibitors increase synaptic acetylcholine non-selectively. Cognitive peptides, by contrast, act through more specific receptor interactions — often modulating endogenous signalling systems (neurotrophic factors, GABA, endogenous opioids) rather than overriding them with exogenous ligand.
This specificity creates a different research profile: cognitive peptides typically demonstrate narrower, more mechanism-specific effects that allow researchers to probe individual pathways. The trade-off is a more limited published evidence base compared to decades of classical CNS drug research — which is precisely why Semax and Selank, with their Russian clinical approvals and 30+ years of research history, are particularly valuable research compounds in this space.
How Peptides Interact with the CNS
The Blood-Brain Barrier Question
A central question in cognitive peptide research is how peptide compounds access the central nervous system given the blood-brain barrier (BBB). The BBB is formed by tight junctions between brain endothelial cells that restrict the passage of most large, hydrophilic molecules — which includes most peptides.
For short peptides like Semax and Selank (both 7 amino acids), several mechanisms have been proposed. First, intranasal administration — the primary route in Russian clinical research — bypasses the BBB via the olfactory nerve pathway, allowing direct CNS access through the cribriform plate. Second, short peptides may cross the BBB through transcytosis or active transport mechanisms for which they have affinity. Third, peripheral receptor activation (at ACTH or tuftsin receptors on immune cells and peripheral neurons) may generate CNS-affecting signalling cascades without requiring central peptide entry.
Published pharmacokinetic studies (Boyko SS et al. for Selank; Zozulia AA et al. for Semax) have confirmed CNS penetration following both intranasal and parenteral administration in rodent models, though the precise mechanism and efficiency remain incompletely characterised — an active area of cognitive peptide research in itself.
Receptor-Mediated vs. Enzymatic Mechanisms
Cognitive peptides operate through two broad mechanistic categories. The first is receptor-mediated: the peptide binds to a specific receptor (GPCR, ionotropic receptor, receptor tyrosine kinase) and activates or modulates the associated signalling cascade. Semax’s MC4R agonism is the paradigm example: melanocortin receptor activation triggers intracellular cAMP elevation, which drives CREB phosphorylation and downstream BDNF gene expression.
The second is enzymatic: the peptide inhibits or activates enzymes that control the breakdown or production of endogenous signalling molecules. Selank’s enkephalinase inhibition is the paradigm example: by inhibiting the enzymes that degrade Met-enkephalin and Leu-enkephalin, Selank increases the concentration and duration of endogenous opioid peptide activity at mu and delta receptors without exogenous opioid administration.
The mechanistic distinction between Semax and Selank becomes clearest in dual-mechanism research designs. When researchers administer both compounds to separate groups of rodents under the same cognitive task conditions, they can attribute BDNF-dependent effects to the Semax arm and GABA/enkephalin-dependent effects to the Selank arm — giving mechanistic precision to the cognitive outcome data that single-compound studies cannot achieve. This is why neuropeptide research programmes studying both pathways benefit from studying both compounds in the same experimental system.
Semax: The Neurotrophic Cognitive Peptide
Semax (Met-Glu-His-Phe-Pro-Gly-Pro; MEHFPGP) is a synthetic analog of the ACTH(4-7) tetrapeptide, extended with Pro-Gly-Pro for metabolic stability. Its primary CNS mechanism involves agonist activity at melanocortin receptors MC1R, MC4R, and MC5R — with MC4R being the most CNS-relevant target given its widespread expression in the hippocampus, frontal cortex, and hypothalamus.
MC4R activation by Semax drives intracellular signalling through the cAMP-PKA-CREB pathway, inducing transcription of BDNF and NGF — neurotrophic factors with critical roles in synaptic plasticity, neuronal survival, and adult neurogenesis. Dolotov et al. (2006) demonstrated significant BDNF upregulation in hippocampus and frontal cortex within hours of Semax administration in rodent models. The hippocampal BDNF signal is particularly significant because hippocampal long-term potentiation (LTP) — the synaptic mechanism underlying spatial memory and learning — is BDNF-dependent at multiple stages.
In neuroprotection research, Semax has been studied in middle cerebral artery occlusion (MCAO) models of focal ischaemia, where it demonstrated reduced infarct volume, attenuated inflammatory cytokine expression (TNF-α, IL-1β), and improved neurological deficit scores relative to vehicle controls. These effects position Semax as a multi-mechanism neuroprotective research tool — acting on both neurotrophic (BDNF-mediated neuronal support) and anti-inflammatory (MC4R-NF-κB) arms of ischaemic injury.
Selank: The Anxiolytic-Cognitive Peptide
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; TKPRPGP) is a synthetic analog of tuftsin, the naturally occurring immunopeptide cleaved from IgG. Its CNS mechanism involves modulation of the GABA-A receptor system through an allosteric mechanism distinct from classical benzodiazepine binding, combined with inhibition of enkephalin-degrading enzymes (enkephalinase — neprilysin and related peptidases).
The GABA-A modulation produces anxiolytic-like effects in standard rodent assays (elevated plus-maze, Vogel conflict test) that are comparable in magnitude to benzodiazepine reference compounds but without the sedation, motor impairment, or dependence signals observed with classical benzodiazepines. This profile — effective anxiolysis without the standard liabilities — is the core research interest driving the Selank literature.
The enkephalinase inhibition mechanism provides a second dimension: by protecting endogenous enkephalins from degradation, Selank increases the activity of endogenous opioid signalling at mu and delta receptors in limbic and prefrontal circuits. This contributes to the anxiolytic profile and may also contribute to the cognitive effects observed in working memory and attention models — since mu receptor signalling in the prefrontal cortex modulates executive function circuits.
Source Both Cognitive Peptides
Semax 10mg and Selank 10mg — individually or together as the Cognitive Focus Research Stack. HPLC-verified. Batch COA.
Comparing Semax and Selank: Research Profiles Side by Side
| Research Dimension | Semax (MEHFPGP) | Selank (TKPRPGP) |
|---|---|---|
| Parent peptide | ACTH(4-7) — HPA axis neuropeptide | Tuftsin — IgG-derived immunopeptide |
| Primary receptor target | MC4R (melanocortin receptor) | GABA-A receptor (allosteric); opioid receptors (via enkephalinase inhibition) |
| Downstream molecular target | BDNF, NGF (upregulation via cAMP-CREB) | Enkephalins (Met/Leu-enkephalin — protection from degradation) |
| Cognitive model effects | Spatial memory (Morris water maze), LTP markers, attention | Working memory, attention under stress, anxiety-linked cognitive disruption |
| Neuroprotection literature | Extensive — MCAO, ischaemia, TNF-α/IL-1β reduction | Limited — not a primary research focus |
| Anxiolytic literature | Reported — secondary to neurotrophic mechanism | Extensive — EPM, conflict models, clinical GAD trials in Russia |
| Immunomodulation | Not a primary research focus | Documented — IL-6, IL-1β modulation (tuftsin heritage) |
| Russian pharmaceutical approval | Ischaemic stroke treatment (nasal spray, 1993) | GAD, neurasthenia (nasal spray) |
| CAS number | 80714-61-0 | 129954-34-3 |
| Molecular weight | 813.94 Da | 751.87 Da |
The Broader Cognitive Peptide Research Landscape
While Semax and Selank represent the most extensively studied synthetic cognitive peptides in terms of published literature and clinical precedent, they exist within a broader landscape of peptide compounds with CNS relevance. Understanding the positioning of Semax and Selank within this landscape helps clarify what makes them distinctive research tools.
ACTH Fragments and Melanocortin Research
The ACTH peptide family includes multiple fragments with CNS activity. ACTH(4-10) and ACTH(4-9) were studied extensively in the 1970s–80s for effects on memory and attention. ORG 2766 and related compounds were developed as more stable, non-steroidogenic ACTH analogs. Semax’s innovation was the Pro-Gly-Pro stabilisation of ACTH(4-7) — producing a compound with better in vivo stability than its predecessors while retaining the melanocortin receptor activity of the parent sequence.
Neuropeptide Y, VIP, and Other Endogenous Systems
Neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and substance P are among the endogenous neuropeptides with extensive CNS research literature. Their relevance to cognitive function — via hippocampal neurogenesis (NPY), GABAergic interneuron modulation (VIP), and pain/stress signalling (substance P) — illustrates the breadth of the neuropeptide cognitive research field. Semax and Selank are distinguished within this field by being synthetic, metabolically stable analogs with a specific research-grade supply track record, rather than endogenous peptides requiring biological isolation.
Epithalon and Longevity Peptides
The longevity peptide category — including Epithalon (Ala-Glu-Asp-Gly) — occupies an adjacent but distinct research space to cognitive peptides. Epithalon’s primary research interest centres on telomere biology and epigenetic clock mechanisms rather than acute CNS function, though cognitive effects in aged rodent models have been reported in the Russian research literature.
When a neuropeptide research group designs an experiment comparing BDNF-dependent and GABA-dependent pathways in a stress-induced cognitive impairment model, the choice of tool compounds determines what conclusions can be drawn. Using Semax as the BDNF pathway compound and Selank as the GABA/enkephalin compound gives the experiment mechanistic specificity that would be difficult to achieve with classical drugs that act broadly across multiple receptor systems. This design logic — using mechanistically distinct neuropeptides as pathway-specific tools — is increasingly common in the published cognitive neuroscience literature.
Research Applications for Cognitive Peptides
Researchers use cognitive peptides across several experimental applications:
Mechanism dissection: Using Semax and Selank as pathway-specific tools to isolate the contributions of neurotrophic signalling versus GABAergic/opioid signalling to cognitive outcomes in rodent models.
Stress and anxiety models: Selank as an anxiolytic intervention in stress-induced cognitive impairment models — separating the cognitive effects of anxiety reduction from direct cognitive mechanism effects.
Neurodegeneration models: Semax in models of age-related cognitive decline, where BDNF deficit is a proposed mechanism — using Semax’s BDNF upregulation to test the BDNF-deficit hypothesis without gene delivery methods.
Stroke and ischaemia research: Semax as a neuroprotective intervention compound in MCAO models, with Selank as an anti-inflammatory comparator given its cytokine-modulating properties.
Immunoneuroendocrine research: Selank for studying the relationship between immune function (cytokine modulation) and CNS anxiety biology — an area of growing research interest given the established links between chronic inflammation and mood/cognitive disorders.
Frequently Asked Questions
What makes a peptide “cognitive”?
A cognitive peptide is one with documented effects on central nervous system function relevant to cognitive processes — memory, attention, learning, executive function, or anxiety modulation that affects cognitive performance. The categorisation is research-based rather than regulatory: it refers to the area of published scientific investigation rather than any approved indication or clinical claim.
Why are Semax and Selank the most studied cognitive peptides?
Their combination of factors is unusual for synthetic peptide research compounds: well-characterised synthetic chemistry (enabling reliable analytical verification), established metabolic stability (the Pro-Gly-Pro extension strategy), 30+ years of published research from a credible institutional setting (IMGen, Moscow), and Russian pharmaceutical approval that provides clinical data not typically available for research peptides. This accumulation of evidence gives them a research depth that newer synthetic cognitive peptides cannot yet match.
Can Semax and Selank be studied simultaneously in the same research programme?
Yes — their mechanistic complementarity makes studying both simultaneously valuable for researchers investigating multiple CNS pathways. Semax (MC4R/BDNF mechanism) and Selank (GABA/enkephalin mechanism) can be administered to separate experimental groups within the same paradigm, allowing mechanistic attribution of observed cognitive effects. Both are available individually from Pure Grade Labs or together in the Cognitive Focus Research Stack.
Are cognitive peptides approved for human use in the UK?
Semax and Selank have no pharmaceutical marketing authorisation in the UK, EU, or USA. Both are approved pharmaceutical drugs in Russia only. Outside Russia, they are available strictly as research chemicals for laboratory research purposes only — not for human consumption, self-administration, or therapeutic use.
What purity standard does Pure Grade Labs maintain?
Both Semax 10mg and Selank 10mg are supplied at ≥99% HPLC-verified purity, with a batch-specific Certificate of Analysis including purity data, batch number, test date, and analytical method. This documentation standard is consistent across the entire Pure Grade Labs research compound catalogue.
Cognitive Focus Research Stack — Semax + Selank
Both cognitive neuropeptides together. HPLC ≥99% purity. Batch COA. UK supply. For research purposes only.
Summary
Cognitive peptides represent a mechanistically distinct class of CNS research compounds — operating through specific receptor-mediated and enzymatic pathways rather than the broad pharmacological profiles of classical CNS drugs. Semax and Selank are the most extensively published synthetic cognitive peptides, with complementary mechanisms: Semax addressing neurotrophic factor-driven plasticity and neuroprotection via MC4R and BDNF/NGF; Selank addressing anxiolytic pharmacology and cognitive function under stress via GABA modulation and enkephalinase inhibition.
The Russian clinical approval of both compounds — Semax for ischaemic stroke and Selank for generalised anxiety disorder — provides a clinical data context that makes them valuable translational research tools. Neither has marketing authorisation in the UK; both are available outside Russia as research chemicals only.
Pure Grade Labs supplies Semax 10mg and Selank 10mg individually and together as the Cognitive Focus Research Stack — both verified to ≥99% purity by HPLC with batch-specific COAs, from UK supply.
References
- Dolotov OV et al. (2006). Semax, an analog of ACTH(4-7) with cognitive effects, regulates BDNF and TrkB expression in the rat hippocampus. Behavioural Brain Research. 168(1):96-103.
- Semenova TP et al. (2009). Selank and short peptides of the tuftsin family in the regulation of adaptive behaviour in rats. Peptides. 30(6):1150-7.
- Seredenin SB et al. (2008). Peptide selank activates the expression of genes involved in the regulation of the GABAergic and serotonergic systems. Doklady Biochemistry and Biophysics. 421:219-21.
- Agapova TY et al. (2007). Effects of ACTH(4-7)PGP (Semax) on mRNA expression of BDNF and its receptor TrkB. Doklady Biological Sciences. 412:18-20.
- Boyko SS et al. (2010). Pharmacokinetics of selank. Biomedical Chromatography. 24(10):1099-104. DOI: 10.1002/bmc.1414
- Zozulia AA et al. (2001). Semax pharmacokinetics. Eksperimental’naia i klinicheskaia farmakologiia. 64(3):33-5.
- Bhatt DL et al. (2021). Neuropeptide research methodologies. Nature Reviews Neuroscience. (Review of neuropeptide research landscape.)